These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9510501)

  • 21. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
    Mohammad RM; Wang S; Aboukameel A; Chen B; Wu X; Chen J; Al-Katib A
    Mol Cancer Ther; 2005 Jan; 4(1):13-21. PubMed ID: 15657349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.
    Huang MQ; Nelson DS; Pickup S; Qiao H; Delikatny EJ; Poptani H; Glickson JD
    Acad Radiol; 2007 Dec; 14(12):1531-9. PubMed ID: 18035282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.
    Beckwith M; Urba WJ; Longo DL
    J Natl Cancer Inst; 1993 Mar; 85(6):483-8. PubMed ID: 8445676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
    Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
    Hornung RL; Pearson JW; Beckwith M; Longo DL
    Cancer Res; 1992 Jan; 52(1):101-7. PubMed ID: 1727368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
    Grant S; Jarvis WD; Swerdlow PS; Turner AJ; Traylor RS; Wallace HJ; Lin PS; Pettit GR; Gewirtz DA
    Cancer Res; 1992 Nov; 52(22):6270-8. PubMed ID: 1423273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification.
    Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR
    Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.
    Barr PM; Lazarus HM; Cooper BW; Schluchter MD; Panneerselvam A; Jacobberger JW; Hsu JW; Janakiraman N; Simic A; Dowlati A; Remick SC
    Am J Hematol; 2009 Aug; 84(8):484-7. PubMed ID: 19536846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of selected natural products as therapeutic agents against cancer.
    Banerjee S; Wang Z; Mohammad M; Sarkar FH; Mohammad RM
    J Nat Prod; 2008 Mar; 71(3):492-6. PubMed ID: 18302335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
    Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
    Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
    Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Durkin KP; Boyd MR; Bai R; Hamel E; Schmidt JM; Chapuis JC
    Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.
    Jarvis WD; Povirk LF; Turner AJ; Traylor RS; Gewirtz DA; Pettit GR; Grant S
    Biochem Pharmacol; 1994 Mar; 47(5):839-52. PubMed ID: 8135859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.
    Wang H; Mohammad RM; Werdell J; Shekhar PV
    Int J Mol Med; 1998 Jun; 1(6):915-23. PubMed ID: 9852625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
    Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
    Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum.
    Fennell BJ; Carolan S; Pettit GR; Bell A
    J Antimicrob Chemother; 2003 Apr; 51(4):833-41. PubMed ID: 12654761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937).
    Wang S; Guo CY; Castillo A; Dent P; Grant S
    Biochem Pharmacol; 1998 Sep; 56(5):635-44. PubMed ID: 9783732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).
    Vrana JA; Saunders AM; Chellappan SP; Grant S
    Differentiation; 1998 May; 63(1):33-42. PubMed ID: 9615391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.